Developing a universal vaccine for coronaviruses using nanoparticles
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles
['FUNDING_P01'] · WISTAR INSTITUTE · NIH-10328138
This study is working on a new type of vaccine that could help protect you from several coronaviruses, including the one that causes COVID-19, by boosting your immune system and keeping it strong against changes in the virus.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10328138 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a universal vaccine that can provide immunity against multiple coronaviruses, including SARS-CoV-2, which causes COVID-19. The approach involves using nucleic acid delivered nanoparticles to enhance the immune response and address challenges such as vaccine longevity and emerging viral mutations. By studying how different vaccine components interact with the immune system, the researchers aim to develop a vaccine that can effectively protect against both current and future coronavirus threats.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for severe COVID-19 or those who may benefit from enhanced immunity against coronaviruses.
Not a fit: Patients who are not at risk for coronavirus infections or those who have already been vaccinated with effective vaccines may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that offers broad protection against various coronaviruses, potentially preventing future pandemics.
How similar studies have performed: Other research has shown promise in developing vaccines using similar nanoparticle approaches, indicating potential for success in this novel application.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WEINER, DAVID B. — WISTAR INSTITUTE
- Study coordinator: WEINER, DAVID B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.